Types of Blood Cancer: Which Ones Are Treated With Stem Cell Transplant or CAR-T Therapy?

What This Article Covers

Blood cancer is not one disease but a broad family of conditions that begin in the bone marrow, blood, or lymphatic system, and the treatment options differ dramatically depending on exact subtype. Two of the most talked-about cell-based treatments — hematopoietic stem cell transplant (HSCT) and CAR-T (chimeric antigen receptor T-cell) therapy — have genuinely transformed outcomes for several blood cancers, but neither is interchangeable, and neither is available or appropriate across the whole category. This article walks through the major classes of blood cancer — leukemias, lymphomas, multiple myeloma, and myelodysplastic syndromes — and lays out, subtype by subtype, which ones have FDA-approved CAR-T products today, which rely on traditional stem cell transplant, and which still have no approved cell therapy at all.

How Blood Cancers Are Classified

Blood cancers fall into three broad groups based on the cell type involved: leukemias (cancers of blood-forming cells, usually in the marrow), lymphomas (cancers of the lymphatic system, split into Hodgkin and non-Hodgkin lymphoma), and plasma cell disorders like multiple myeloma. Myelodysplastic syndromes (MDS) sit alongside these as a group of marrow disorders that can behave like a slow-building leukemia. Each of these categories has further subtypes defined by the specific cell of origin and genetic features, and that granularity matters enormously for treatment: CAR-T therapy, in particular, is only approved for cancers that express the exact surface protein (such as CD19 or BCMA) the engineered T-cells are built to recognize.

Leukemias: Where CAR-T Has Made Real Inroads — and Where Transplant Still Leads

• Acute lymphoblastic leukemia (ALL): This is where cell therapy has had its biggest and earliest win. Kymriah (tisagenlecleucel) became the first CAR-T product ever approved by the FDA, in 2017, specifically for children and young adults up to age 25 with relapsed or refractory B-cell ALL — a population in which 83% of treated patients achieved remission within three months in the pivotal trial. Tecartus (brexucabtagene autoleucel) is separately approved for relapsed or refractory B-cell precursor ALL in adults. Allogeneic stem cell transplant remains an important option for higher-risk or relapsed ALL as well, often used alongside or after CAR-T.
• Acute myeloid leukemia (AML): There is no FDA-approved CAR-T therapy for AML today. Allogeneic stem cell transplant remains the primary curative-intent cell therapy for eligible higher-risk patients, and CAR-T approaches for AML remain investigational, partly because AML cells lack a single clean target shared by healthy blood stem cells.
• Chronic lymphocytic leukemia (CLL): CAR-T is not yet FDA-approved for CLL itself, though it is approved for small lymphocytic lymphoma (SLL), its close relative, via Breyanzi (lisocabtagene maraleucel) for patients who've had two or more prior lines of therapy. CLL/SLL CAR-T research is active and promising, but for most CLL patients today, treatment centers on targeted oral drugs; stem cell transplant is used far less often than it once was and is generally reserved for higher-risk or treatment-resistant disease.
• Chronic myeloid leukemia (CML): Highly effective targeted pills (tyrosine kinase inhibitors) have made CML one of the most successfully managed blood cancers without cell therapy for most patients; transplant is reserved for rare treatment-resistant or advanced-phase cases, and there is no approved CAR-T option.

Lymphomas: The Broadest FDA-Approved CAR-T Footprint

Non-Hodgkin lymphoma (NHL) — especially aggressive B-cell subtypes — has the widest range of FDA-approved CAR-T options of any blood cancer category:

• Large B-cell lymphoma: Approved CAR-T options include Yescarta (axicabtagene ciloleucel), Breyanzi, and Kymriah, each for relapsed or refractory disease after prior lines of therapy, with some now approved for earlier relapse as well.
• Follicular lymphoma: Yescarta, Breyanzi, and Kymriah are each approved here too, after two or more prior treatments.
• Mantle cell lymphoma: Tecartus and Breyanzi are approved for relapsed or refractory disease.
• Hodgkin lymphoma: No CAR-T product is FDA-approved for Hodgkin lymphoma. Autologous stem cell transplant is the established standard for patients who relapse after initial chemotherapy, and allogeneic transplant is used in select relapsed/refractory cases; CAR-T remains investigational here.

Across these B-cell lymphoma indications, trial-reported response rates have been striking — a meaningful share of heavily pretreated patients achieve complete remission — which is genuinely one of the most encouraging developments in recent oncology. That said, these approvals are for relapsed or refractory disease, generally after at least one or two standard treatments have already been tried, not as an upfront replacement for chemoimmunotherapy.

Multiple Myeloma and Plasma Cell Disorders

Multiple myeloma now has two FDA-approved CAR-T products targeting BCMA, a protein on myeloma cells: Abecma (idecabtagene vicleucel) and Carvykti (ciltacabtagene autoleucel), both for relapsed or refractory disease after multiple prior therapies. At the same time, high-dose chemotherapy followed by autologous stem cell transplant remains a long-established standard of care for eligible myeloma patients, frequently used earlier in the treatment course than CAR-T. The two approaches aren't competing so much as sequential options many patients may encounter at different points in their disease.

Myelodysplastic and Myeloproliferative Conditions

Myelodysplastic syndromes (MDS) have no FDA-approved CAR-T therapy. For patients with higher-risk MDS, allogeneic stem cell transplant remains the only treatment with real curative potential, though it carries substantial risk and is not suitable for everyone, particularly older patients or those with other health conditions. Myeloproliferative neoplasms (such as myelofibrosis) similarly rely on transplant in appropriate candidates rather than any approved cell therapy.

The Real Trade-Offs Worth Knowing

Both treatments carry serious, well-documented risks that any accurate overview has to include. CAR-T therapy commonly causes cytokine release syndrome (CRS), an inflammatory reaction that can range from mild fever to life-threatening organ dysfunction, along with a risk of neurological side effects; both are manageable at experienced centers but require close monitoring. Allogeneic stem cell transplant carries its own major risk in graft-versus-host disease (GVHD), where donor immune cells attack the recipient's healthy tissue — acute GVHD affects roughly 30% to 70% of allogeneic transplant recipients, and chronic GVHD develops in an estimated 40% to 50%, according to the Leukemia & Lymphoma Society. Neither treatment is risk-free, and eligibility depends heavily on disease subtype, prior treatment, and overall health.

Bottom Line

Stem cell transplant and CAR-T therapy are two of the most important advances in blood cancer treatment, but they are not universal solutions — each is approved for specific subtypes and specific points in the disease course. CAR-T has secured real, FDA-approved footholds in certain B-cell lymphomas, B-cell ALL, and multiple myeloma, with genuinely strong remission rates in difficult-to-treat, relapsed disease. Traditional stem cell transplant remains the backbone of curative-intent treatment for AML, MDS, Hodgkin lymphoma, and as a standard step in myeloma care. Several major blood cancers — including AML, CLL, MDS, and Hodgkin lymphoma — still have no FDA-approved CAR-T option, even though research in these areas is active. Anyone evaluating these treatments should discuss exact subtype, disease stage, and eligibility with a hematologist-oncologist at a center with transplant and cellular therapy expertise.